Fruit Street
-
Member of the Board of Advisors
April 3, 2026
Sierra Medical is advancing a clinically validated infrared spectral intelligence platform powered by explainable AI.
Its first deployment, AIR-DS Lung, applies spectral pattern recognition to early lung cancer detection using standard laboratory infrastructure and has demonstrated greater than 90 percent accuracy in validation settings.
Over the past quarter, Sierra Medical has entered a major expansion phase marked by several milestones:
IRB approval secured at a major U.S. cancer center
Thirteen sites participating in the RADICAL-REACT multi-center validation study
Successful launch of AIR-DS Version 1.0.0, the company’s first clinically deployable diagnostic system
Expanded U.S. presence with new operations, clinical leadership, and advocacy partnerships
Early discussions underway with U.S. and U.K. venture funds
Growing demand from CLIA and ISO laboratories, health systems, and cancer networks
Sierra Medical is now transitioning from clinical validation toward structured commercialization.
As part of this next phase, the company is selectively expanding its Board.
Sierra Medical is forming a curated group of Executive Board Partners aligned with the commercialization and long-term expansion of its spectral intelligence platform.
This role differs from formal board membership but operates closely with governance and ownership. Executive Board Partners participate as senior operators and capital allocators who engage at a critical inflection point in the company’s growth.
Participation is intentionally limited and highly selective.
Sierra Medical’s immediate focus is healthcare deployment.
However, the combination of infrared spectroscopy and AI-driven spectral interpretation represents a foundational analytical capability capable of enabling real-time molecular fingerprinting and compositional analysis.
While healthcare remains the first regulated commercialization pathway, spectral intelligence has broader long-term potential across multiple industries including:
Advanced materials and aerospace composites
Industrial chemical and energy analysis
Agriculture and soil diagnostics
Infrastructure and non-destructive testing
Environmental and analytical screening
Executive Board Partners join the company at a stage where the platform has validated in a highly regulated environment and is transitioning toward revenue generation.
Executive Board Partners contribute through strategic dialogue around commercialization and scaling, providing insight into cross-sector expansion opportunities, and participating in capital-aligned ownership.
They offer a long-term platform perspective and gain visibility into governance-level decision making.
Engagement is strategic and periodic rather than operational.
This is an equity-based board role aligned with ownership participation in the company. Executive Board participation is designed for individuals who view strategic contribution and capital alignment as interconnected.
The role does not include cash compensation.
Sierra Medical is seeking senior executives with at least ten years of leadership experience in one or more of the following areas:
Healthcare systems, diagnostics, or regulated commercialization
Deep technology or AI and machine learning infrastructure
Advanced materials, aerospace, or energy innovation
Industrial analytics or analytical instrumentation markets
Enterprise software or data-driven technical platforms
Executive leadership positions such as CEO, COO, CTO, CCO, President, or SVP of Engineering
Angel investing, venture participation, or principal capital allocation
Prior board, governance, or strategic oversight experience
The company is particularly interested in leaders who think in platform terms, have scaled technical infrastructure into complex markets, operate comfortably within regulated or compliance-driven environments, and engage as long-term owners rather than external advisors.
AIR-DS is now clinically deployable.
Multi-site validation is active.
Commercial infrastructure has been established.
The platform sits at a convergence point between scientific validation, regulatory progress, and market demand.
Board expansion at this stage offers the opportunity to participate during a defined commercialization inflection point.
Sierra Medical is committed to building a diverse, inclusive, and clinically representative Board. The company welcomes applicants from all backgrounds and does not discriminate based on race, gender, ethnicity, disability, age, religion, or any protected characteristic.
The organization believes diverse leadership perspectives across clinical, commercial, and investment experience strengthen its mission to make early and accessible disease detection a global reality.
.webp)
